Board Member
Capricor Therapeutics, Inc. (CAPR)Equibles does not estimate personal net worth.
Get an email with a short summary when Capricor Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get CAPR alertsLinda Marban is recorded as Board Member at Capricor Therapeutics, Inc. (CAPR) since January 1, 2013 and CEO at Capricor Therapeutics, Inc. (CAPR). The newest filing on record that lists Linda Marban as CEO and Board Member at Capricor Therapeutics, Inc. (CAPR) is dated April 10, 2026. The proxy statement of Capricor Therapeutics, Inc. reports total compensation of $1,657,032 for Linda Marban in fiscal 2020, including a base salary of $150,000. Disclosed compensation is on record for 3 fiscal years. Linda Marban has spoken on 26 earnings calls and 1 other investor event across 1 company, most recently for Capricor Therapeutics, Inc. on November 10, 2026. Capricor Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Capricor Therapeutics, Inc. includes Frank Litvack (Chairman and Board Member), Anthony "A.J." Bergmann (CFO), Karen G. Krasney (General Counsel) and 7 others.
“Let me remind you that as Duchenne muscular dystrophy progresses, boys and young men lose the use of their arms and hands, the ability to feed themselves, use a phone or computer, or handle the everyday tasks that keep them independent.”
“Good afternoon, everyone, and thank you for joining Capricor's second quarter 2026 earning calls. Our BLA for DERM-ISL remains under review with the FDA with a current PDUFA target action date of August 22nd.”
“So it's been a really tumultuous year for Capricorn from a regulatory perspective, but we feel like we are coming out on top. As people may remember, last year our adcom was canceled at the last minute.”
“Good afternoon, everyone, and thank you for joining Capricor's first quarter 2026 earnings call. To our investors, collaborators, the Capricor team, and especially the Duchenne patient community, thank you for your continued support and belief in our mission.”
“Good afternoon, everyone, and thank you for joining us on Capricor Therapeutics, Inc.’s quarterly conference call.”
2013-01-01–present
Last confirmed April 10, 2026
Start not stated–present
Last confirmed April 10, 2026
Biotechnology · Healthcare
CEO, Board Member
2013-01-01–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2020 | Capricor Therapeutics, Inc. (CAPR) | Chief Executive Officer | $150,000 | $1,657,032 |
| 2019 | Capricor Therapeutics, Inc. (CAPR) | Chief Executive Officer | $156,909 | $228,919 |
| 2018 | Capricor Therapeutics, Inc. (CAPR) | Chief Executive Officer ^^ | $232,909 | $377,471 |
